top of page

USFDA Guidance: Format and Content for OTC Monograph Order Requests

Writer's picture: Sharan MuruganSharan Murugan

Earlier today (12 April 2023) USFDA's Center for Drug Evaluation and Research released a draft guidance on"Over-the-Counter Monograph Order Requests: Format and Content".


Over-the-Counter (OTC) medications are drugs that can be purchased without a prescription from a healthcare provider.

These drugs are regulated by the United States Food and Drug Administration (FDA) through the OTC Monograph system. The OTC Monograph system is a set of regulations that establish the safety, efficacy, and labeling requirements for certain OTC drug products.

This guidance is intended to assist requestors in preparing over-the-counter (OTC) monograph order requests (OMORs) for submission to FDA and provides FDA's recommendations on the format and content of the information requestors should provide in an OMOR as well as identifies relevant guidance documents to assist requestors in preparing their OMOR.


A drug manufacturer must submit an Order Request to the FDA if they wish to market an OTC product covered by a monograph. The Order Request is a formal document that outlines the manufacturer's intent to market the product and includes all of the necessary information about it.


Requestors can request a formal meeting with FDA to discuss specific data, studies, and related information to be submitted in the OMORs.


OMORs should adhere to the organizational structure and format specified in the Common Technical Specification for the Registration of Medicines for Human Use, and they must be submitted electronically (CTD).


Click this LINK to know more exclusively on the Format and Content for OTC Monograph Order Requests.

コメント


I Sometimes Send Newsletters

Thanks for submitting!

  • LinkedIn
  • Facebook
  • Twitter
  • Instagram

DISCLAIMER

The views expressed in this publication do not necessarily reflect the views of any guidance of government, health authority, it's purely my understanding. This Blog/Web Site is made available by a regulatory professional, is for educational purposes only as well as to give you general information and a general understanding of the pharmaceutical regulations, and not to provide specific regulatory advice. By using this blog site you understand that there is no client relationship between you and the Blog/Web Site publisher. The Blog/Web Site should not be used as a substitute for competent pharma regulatory advice and you should discuss from an authenticated regulatory professional in your state.  We have made every reasonable effort to present accurate information on our website; however, we are not responsible for any of the results you experience while visiting our website and request to use official websites.

bottom of page